Drug Profile
CAT 3888
Alternative Names: BL 22; BL22 Immunotoxin - AstraZeneca; GCR 3888; RFB4 (dsFv) PE38Latest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Cambridge Antibody Technology; National Institutes of Health (USA)
- Developer MedImmune
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Hairy cell leukaemia; Lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 29 Oct 2007 Cambridge Antibody Technology has been integrated into MedImmune
- 22 Jun 2006 Cambridge Antibody Technology has been acquired by AstraZeneca
- 24 May 2006 AstraZeneca to acquire CAT 3888 as part of company acquisition